Alector, Inc. (NASDAQ:ALEC) Receives Average Recommendation of “Hold” from Analysts

Alector, Inc. (NASDAQ:ALEC) has received an average recommendation of “Hold” from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $4.00.

Separately, HC Wainwright boosted their price target on shares of Alector from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, May 9th.

Alector Trading Down 6.4%

Alector stock opened at $1.61 on Wednesday. The company has a 50 day moving average price of $1.39 and a 200 day moving average price of $1.45. Alector has a 52 week low of $0.87 and a 52 week high of $6.78. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.34 and a current ratio of 3.34. The firm has a market capitalization of $160.98 million, a price-to-earnings ratio of -1.28 and a beta of 0.74.

Institutional Investors Weigh In On Alector

A number of institutional investors have recently modified their holdings of the company. Strs Ohio bought a new position in Alector during the first quarter worth $126,000. Acadian Asset Management LLC boosted its stake in Alector by 39.8% during the first quarter. Acadian Asset Management LLC now owns 1,440,661 shares of the company’s stock worth $1,768,000 after acquiring an additional 410,205 shares in the last quarter. Jane Street Group LLC boosted its stake in Alector by 4.7% during the first quarter. Jane Street Group LLC now owns 256,551 shares of the company’s stock worth $316,000 after acquiring an additional 11,618 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in Alector by 25.9% during the first quarter. Jacobs Levy Equity Management Inc. now owns 1,334,032 shares of the company’s stock worth $1,641,000 after acquiring an additional 274,341 shares in the last quarter. Finally, Almitas Capital LLC boosted its stake in Alector by 12.9% during the first quarter. Almitas Capital LLC now owns 321,568 shares of the company’s stock worth $396,000 after acquiring an additional 36,723 shares in the last quarter. 85.83% of the stock is owned by institutional investors.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.